CONTEXT: Cancer registries have reported an increased incidence of melanoma and certain noncutaneous cancers following nonmelanoma skin cancer (NMSC). Whether these findings were attributable to intensified surveillance, shared risk factors, or increased cancer susceptibility remains unclear. OBJECTIVE: To determine whether a history of NMSC predicts cancer mortality. DESIGN: Prospective cohort with 12-year mortality follow-up adjusted for multiple risk factors. SETTING: Cancer Prevention Study II, United States and Puerto Rico. PARTICIPANTS: Nearly 1.1 million adult volunteers who completed a baseline questionnaire in 1982. MAIN OUTCOME MEASURE: Deaths due to all cancers and common cancers. RESULTS: After adjusting for age, race, education, smoking, obesity, alcohol use, and other conventional risk factors, a baseline history of NMSC was associated with increased total cancer mortality (men's relative risk [RR], 1.30; 95% confidence interval [CI], 1.23-1.36; women's RR, 1.26; 95% CI, 1.17-1.35). Exclusion of deaths due to melanoma reduced these RRs only slightly. Mortality was increased for the following cancers: melanoma (RR, 3.36 in men, 3.52 in women); pharynx (RR, 2.77 in men, 2.81 in women); lung (RR, 1.37 in men, 1.46 in women); non-Hodgkin lymphoma (RR, 1.32 in men, 1.50 in women); in men only, salivary glands (RR, 2.96), prostate (RR, 1.28), testis (RR, 12.7), urinary bladder (RR, 1.41), and leukemia (RR, 1.37); and in women only, breast (RR, 1.34). All-cause mortality was slightly increased (adjusted men's RR, 1.03 [95% CI, 1.00-1.06]; women's RR, 1.04 [95% CI, 1.00-1.09]). CONCLUSIONS: Persons with a history of NMSC are at increased risk of cancer mortality. Although the biological mechanisms are unknown, a history of NMSC should increase the clinician's alertness for certain noncutaneous cancers as well as melanoma.
CONTEXT: Cancer registries have reported an increased incidence of melanoma and certain noncutaneous cancers following nonmelanoma skin cancer (NMSC). Whether these findings were attributable to intensified surveillance, shared risk factors, or increased cancer susceptibility remains unclear. OBJECTIVE: To determine whether a history of NMSC predicts cancer mortality. DESIGN: Prospective cohort with 12-year mortality follow-up adjusted for multiple risk factors. SETTING:Cancer Prevention Study II, United States and Puerto Rico. PARTICIPANTS: Nearly 1.1 million adult volunteers who completed a baseline questionnaire in 1982. MAIN OUTCOME MEASURE: Deaths due to all cancers and common cancers. RESULTS: After adjusting for age, race, education, smoking, obesity, alcohol use, and other conventional risk factors, a baseline history of NMSC was associated with increased total cancer mortality (men's relative risk [RR], 1.30; 95% confidence interval [CI], 1.23-1.36; women's RR, 1.26; 95% CI, 1.17-1.35). Exclusion of deaths due to melanoma reduced these RRs only slightly. Mortality was increased for the following cancers: melanoma (RR, 3.36 in men, 3.52 in women); pharynx (RR, 2.77 in men, 2.81 in women); lung (RR, 1.37 in men, 1.46 in women); non-Hodgkin lymphoma (RR, 1.32 in men, 1.50 in women); in men only, salivary glands (RR, 2.96), prostate (RR, 1.28), testis (RR, 12.7), urinary bladder (RR, 1.41), and leukemia (RR, 1.37); and in women only, breast (RR, 1.34). All-cause mortality was slightly increased (adjusted men's RR, 1.03 [95% CI, 1.00-1.06]; women's RR, 1.04 [95% CI, 1.00-1.09]). CONCLUSIONS:Persons with a history of NMSC are at increased risk of cancer mortality. Although the biological mechanisms are unknown, a history of NMSC should increase the clinician's alertness for certain noncutaneous cancers as well as melanoma.
Authors: Christopher P Fagundes; Ronald Glaser; Sheri L Johnson; Rebecca R Andridge; Eric V Yang; Michael P Di Gregorio; Min Chen; David R Lambert; Scott D Jewell; Mark A Bechtel; Dean W Hearne; Joel B Herron; Janice K Kiecolt-Glaser Journal: Arch Gen Psychiatry Date: 2012-06
Authors: Peter A Andersen; David B Buller; Barbara J Walkosz; Michael D Scott; Julie A Maloy; Gary R Cutter; Mark D Dignan Journal: Arch Dermatol Date: 2010-11
Authors: Lindsay Wong; Andrea M Burden; Yan Yun Liu; Mina Tadrous; Nedzad Pojskic; Lisa Dolovich; Andrew Calzavara; Suzanne M Cadarette Journal: Can Pharm J (Ott) Date: 2015-01
Authors: Mackenzie R Wehner; Wilmarie Cidre Serrano; Adi Nosrati; Patrick Michael Schoen; Mary-Margaret Chren; John Boscardin; Eleni Linos Journal: J Am Acad Dermatol Date: 2017-11-13 Impact factor: 11.527
Authors: Virginia Barton; Kent Armeson; Shalaka Hampras; Laura K Ferris; Kala Visvanathan; Dana Rollison; Anthony J Alberg Journal: Arch Dermatol Res Date: 2017-03-11 Impact factor: 3.017
Authors: Maryam M Asgari; Jimmy T Efird; E Margaret Warton; Gary D Friedman Journal: Int J Environ Res Public Health Date: 2010-02-03 Impact factor: 3.390
Authors: David B Buller; Peter A Andersen; Barbara J Walkosz; Michael D Scott; Larry Beck; Gary R Cutter Journal: Contemp Clin Trials Date: 2015-11-22 Impact factor: 2.226